Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill.

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Older adults with high blood pressure who have a higher weight-adjusted waist index (WWI) have a higher risk for stroke, a new study finds.

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

They also suggest that 0.20 mg per kg weight could be the adequate starting dose, although these data should be confirmed in prospective studies in which steroid dose is adjusted to body weight.

Infant growth predicts long-term obesity and cardiovascular disease. Previous interventions designed to prevent obesity in the first 2 years of life have been largely unsuccessful. Obesity prevalence ...

Though under even more duress than he was against the Packers, the second-year quarterback broke through the constraints and emerged victorious over the Colts.

Results from a phase 2b trial (ClinicalTrials.gov Identifier: NCT04707313) showed treatment with danuglipron led to statistically significant reductions in body weight at all tested doses (40mg, 80mg, ...